AIT Therapeutics to Participate in the JMP Securities Life Science Conference

REHOVOT, Israel and NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC: AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced that Steve Lisi, Chief Executive Officer, will conduct investor meetings at the JMP Securities Life Science Conference, taking place on June 20-21, 2017 in New York City.

About AIT Therapeutics Inc. AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications.  The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care.  AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM).  For more information, visit www.AIT-Pharm.com.

CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]

Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989

You May Also Be Interested In

• InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
• Air Canada Finalizes Terms of $800 Million Substantial Issuer Bid
• Voice AI Infrastructure Leader Deepgram to Establish APAC Headquarters in Singapore Following Strategic Investment from EDBI